ASH 2014

Ibrutinib and ABT199 for CLL

Jennifer R. Brown, MD, PhD, at Dana-Farber Cancer Institute in Boston, discusses what she believes are the most important items coming out of ASH for CLL this year. She mentions excellent study results being presented about the drugs ibrutinib and ABT199.

Jennifer Brown, MD, PhD
Video Categories: ASH 2014

Improving Standard of Care Through Variety

Alexander Bastian says the most important thing to come out of ASH that will improve standard of care is the variety of treatments coming available, including a new drug from Amgen for treating ALL.

Alexander Bastian
Video Categories: ASH 2014

Reality of the ASPIRE Study

Ajai Chari, MD, at the Mount Sinai School of Medicine in New York, deliberates on the results of the ASPIRE study as the most important thing to come out of ASH for the myeloma community. He mentions that although the study has very positive indications, the therapy isn’t really appropriate [ Read More ]

Ajai Chari, MD
Video Categories: ASH 2014

Sign me up!
Friends link: prep4certs
070-411 Braindumps
VCP-550 Braindumps
70-483 Braindumps
HP2-K38
642-997
PK0-003
BH0-013
640-875
C4040-129
JN0-332
E20-547
70-462 Braindumps
400-101 Braindumps
070-461 Braindumps